City-based pharma player, Claris Lifesciences Ltd, said the company has completed the sale of its Global Generic Injectables Business to Baxter International Inc (USA) for an enterprise value of $625 million.
The company will discuss with its advisors and identify the most efficient method of transferring a significant majority of the net proceeds to its shareholder. The company expects to communicate the process before October 15, 2017.
Arjun Handa, Vice-Chairman and MD of Claris Lifesciences Ltd said, “Today, the Claris products and business model’s uniqueness has a significant potential to deliver strong growth. We believe Baxter is the best partner suited to take this platform forward and drive the next phase of growth.”
Source: The Hindu Business Line
SGD Pharma collaborates with Prince Sterilization Services to introduce My Sterinity Nasal vials for North America. The RTU Type I glass vials cater to the growing nasal drug delivery market, offering enhanced purity and sterility assurance. Produced at SGD Pharma’s Saint-Quentin-La-Motte facility, the vials ensure quality and supply chain reliability for US biopharma customers.
Johnson & Johnson’s (J&J) blockbuster cancer immunotherapy, Darzalex (daratumumab), has secured European approval for self-administration, marking the first time an oncology injectable has achieved this milestone on the continent.
UCB announced last week that it has selected Gwinnett County, Georgia as the location for its new U.S. biologics manufacturing facility. The campus will be state-of-the art, using a digital-first approach by leveraging AI, robotics, and automation while being natural resources efficient.
